Takeda Pharmaceutical Company Limited (TAK) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $17.85. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of TAK = $4.87 (-72.7% from the current price, the stock appears overvalued).
Valuation: TAK trades at a trailing Price-to-Earnings (P/E) of 81.4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 4.52.
Financials: revenue is $4.6T, +8.7%/yr average growth. Net income is $107.9B, growing at -13.9%/yr. Net profit margin is 2.4% (thin). Gross margin is 65.5% (-3.5 pp trend).
Balance sheet: total debt is $4.5T against $6.9T equity (Debt-to-Equity (D/E) ratio 0.65, moderate). Current ratio is 1.01 (adequate). Debt-to-assets is 31.7%. Total assets: $14.2T.
Analyst outlook: 5 / 6 analysts rate TAK as buy (83%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 35/100 (Fail), Growth 40/100 (Partial), Past 100/100 (Pass), Health 33/100 (Fail), Moat 79/100 (Pass), Future 90/100 (Pass), Income 30/100 (Fail).
